AstraZeneca, Merck Want Calquence Generics Halted
AstraZeneca and Merck have teamed up in Delaware to assert that MSN and Sandoz are infringing six patents with their proposed generic versions of the $500 million cancer drug Calquence....To view the full article, register now.
Already a subscriber? Click here to view full article